FI114802B - Epstein-Barr-virukseen liittyviä peptidejä ja nukleiinihapposekvenssejä - Google Patents
Epstein-Barr-virukseen liittyviä peptidejä ja nukleiinihapposekvenssejä Download PDFInfo
- Publication number
- FI114802B FI114802B FI931109A FI931109A FI114802B FI 114802 B FI114802 B FI 114802B FI 931109 A FI931109 A FI 931109A FI 931109 A FI931109 A FI 931109A FI 114802 B FI114802 B FI 114802B
- Authority
- FI
- Finland
- Prior art keywords
- ebv
- peptide
- antibodies
- vca
- epstein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP92200721 | 1992-03-13 | ||
EP92200721 | 1992-03-13 |
Publications (3)
Publication Number | Publication Date |
---|---|
FI931109A0 FI931109A0 (fi) | 1993-03-12 |
FI931109A FI931109A (fi) | 1993-09-14 |
FI114802B true FI114802B (fi) | 2004-12-31 |
Family
ID=8210477
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI931109A FI114802B (fi) | 1992-03-13 | 1993-03-12 | Epstein-Barr-virukseen liittyviä peptidejä ja nukleiinihapposekvenssejä |
Country Status (13)
Country | Link |
---|---|
US (1) | US5424398A (de) |
EP (2) | EP1225226B1 (de) |
JP (3) | JP4135996B2 (de) |
KR (1) | KR100291247B1 (de) |
AT (2) | ATE222291T1 (de) |
AU (1) | AU666920B2 (de) |
CA (1) | CA2092680C (de) |
DE (2) | DE69334191T2 (de) |
DK (2) | DK0574048T3 (de) |
ES (2) | ES2184735T3 (de) |
FI (1) | FI114802B (de) |
PT (1) | PT574048E (de) |
ZA (1) | ZA931797B (de) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69330966T2 (de) * | 1993-07-23 | 2002-06-06 | Wolf, Hans | DNA-Sequenzen des Epstein-Barr Virus kodierend für ein diagnostisch relevantes Virus-Hüllprotein, durch PCR erhaltene Expressionsklone und Verwendung dieses rekombinanten Antigens in diagnostischen Tests |
EP0649904B1 (de) * | 1993-09-14 | 2003-01-22 | bioMérieux BV | Diagnostische Reagenzien zum Nachweis von Antikörper gegen EBV |
US5834747A (en) | 1994-11-04 | 1998-11-10 | Pixel Instruments | Universal credit card apparatus and method |
DE19526384C2 (de) * | 1995-07-19 | 1997-07-10 | Biotest Ag | Rekombinante autologe Fusionsproteine des Epstein-Barr-Virus, sowie diese enthaltende Testkits zum Nachweis von Epstein-Barr-Virus-spezifischen Antikörpern |
US5813500A (en) * | 1996-03-25 | 1998-09-29 | Tenneco Automotive Inc. | Anti-swish mechanism for a damper |
FR2765688B1 (fr) | 1997-07-04 | 1999-09-10 | Pasteur Institut | Reactif de detection et de suivi des infections provoquees par le virus d'epstein-barr et ses applications |
US7105496B2 (en) * | 1998-07-23 | 2006-09-12 | Northwestern University | Methods and compositions for inhibiting angiogenesis |
US6797691B1 (en) * | 1997-07-23 | 2004-09-28 | Northwestern University | Methods and compositions for inhibiting angiogenesis |
EP1627886A1 (de) * | 1997-10-07 | 2006-02-22 | Ono Pharmaceutical Co., Ltd. | Polypeptide, die dafür kodierende cDNA und deren Verwendung |
DE69940770D1 (de) | 1998-03-04 | 2009-06-04 | Biomerieux Bv | Vervielfältigung und nachweis von ebv barf1 zur diagnose von nasopharyngealen karzinom |
US20030064917A1 (en) * | 1998-07-23 | 2003-04-03 | Crawford Susan E. | Methods and compositions for inhibiting angiogenesis |
US6159950A (en) * | 1998-10-16 | 2000-12-12 | Cornell Research Foundation, Inc. | Method of modulating hair growth |
CA2400948A1 (en) * | 2000-02-25 | 2001-08-30 | Ludwig Institute For Cancer Research | Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins |
AU2002361559A1 (en) * | 2001-09-24 | 2003-04-28 | University Of Pittburgh Of The Commonwealth System Of Higher Education | Anticancer vaccine and diganostic methods and reagents |
US7521053B2 (en) | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
JP2005530716A (ja) * | 2002-03-27 | 2005-10-13 | アメリカ合衆国 | ヒトにおける癌の治療方法 |
US7226755B1 (en) * | 2002-09-25 | 2007-06-05 | The Procter & Gamble Company | HPTPbeta as a target in treatment of angiogenesis mediated disorders |
US7507568B2 (en) * | 2002-09-25 | 2009-03-24 | The Proctor & Gamble Company | Three dimensional coordinates of HPTPbeta |
US6886670B2 (en) * | 2003-09-29 | 2005-05-03 | Tenneco Automotive Operating Company Inc. | Extra support land for valve disc |
DE10307517A1 (de) * | 2003-02-21 | 2004-09-02 | Mikrogen Molekularbiologische Entwicklungs-Gmbh | Von Kapsidantigenen des Epstein-Barr-Virus abgeleitete Peptide und ihre Verwendung |
US6899207B2 (en) | 2003-09-29 | 2005-05-31 | Tenneco Automotive Operating Company Inc. | Extra support area for valve disc |
AU2005255019B2 (en) * | 2004-06-12 | 2011-05-19 | Oregon Health And Science University | Compositions and methods for diagnosis and treatment of orthopoxviruses |
US7278987B2 (en) * | 2004-07-09 | 2007-10-09 | Anthony Solazzo | Ergonomic urological catheterization/irrigation tray |
WO2007044033A2 (en) | 2004-12-07 | 2007-04-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Therapeutic and diagnostic cloned mhc-unrestricted receptor specific for the muc1 tumor associated antigen |
EP2311531A1 (de) | 2005-12-01 | 2011-04-20 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Antivirale Griffithsin-Verbindungen, Zusammensetzungen und Verwendungsverfahren dafür |
EP2172210A1 (de) | 2005-12-23 | 2010-04-07 | Partnership&Corp. Technology Transfer | Synthetische Peptide zur Verwendung als Inhibitoren der Neurotransmiter-Sekretion |
US7868228B2 (en) | 2006-01-31 | 2011-01-11 | Monsanto Technology Llc | Phosphopantetheinyl transferases from bacteria |
NZ571300A (en) | 2006-04-07 | 2011-12-22 | Warner Chilcott Co Llc | Antibodies that bind human protein tyrosine phosphatase beta (HPTPBeta) and uses thereof |
US7795444B2 (en) | 2006-06-27 | 2010-09-14 | Warner Chilcott Company | Human protein tyrosine phosphatase inhibitors and methods of use |
US7589212B2 (en) | 2006-06-27 | 2009-09-15 | Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
US7622593B2 (en) * | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
US8846685B2 (en) | 2006-06-27 | 2014-09-30 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
WO2009158432A2 (en) | 2008-06-27 | 2009-12-30 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
US8748170B2 (en) | 2008-07-25 | 2014-06-10 | University of Pittsburgh—of the Commonwealth System of Higher Education | Polypeptides derived from cyclin B1 and uses thereof |
DK2337791T3 (da) | 2008-10-14 | 2013-11-04 | Monsanto Technology Llc | Anvendelse af fedtsyredesaturaser fra Hemiselmis SPP |
US9096555B2 (en) | 2009-01-12 | 2015-08-04 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome |
DK2451279T3 (da) | 2009-07-06 | 2019-05-20 | Aerpio Therapeutics Inc | Benzosulfonamid derivater forbindelser deraf og deres brug til at forhindre metastaser af cancerceller |
US8883832B2 (en) | 2009-07-06 | 2014-11-11 | Aerpio Therapeutics Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
US20120100166A1 (en) | 2010-07-15 | 2012-04-26 | Zyngenia, Inc. | Ang-2 Binding Complexes and Uses Thereof |
CA2827170A1 (en) | 2011-02-11 | 2012-08-16 | David M. Hilbert | Monovalent and multivalent multispecific complexes and uses thereof |
CA2837169C (en) | 2011-05-24 | 2021-11-09 | Zyngenia, Inc. | Multispecific complexes comprising angiopoietin-2-binding peptide and their uses |
WO2013025479A1 (en) | 2011-08-16 | 2013-02-21 | Emory University | Jaml specific binding agents, antibodies, and uses related thereto |
CN104039351A (zh) | 2011-10-13 | 2014-09-10 | 阿尔皮奥治疗学股份有限公司 | 用于治疗血管渗漏综合征和癌症的方法 |
BR112015023752B1 (pt) | 2013-03-15 | 2023-11-14 | Zyngenia, Inc. | Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo |
EP2813849A1 (de) * | 2013-06-10 | 2014-12-17 | Charité-Universitätsmedizin Berlin (Charité) | EBV-spezifische Immunsignatur als Diagnosemarker bei chronischem Erschöpfungssyndrom (CFS) |
US11034736B2 (en) | 2014-01-09 | 2021-06-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-viral cnidarins |
ES2781085T3 (es) | 2015-02-10 | 2020-08-28 | Us Health | Mutantes de griffithsina |
EP3256144B1 (de) | 2015-02-13 | 2021-03-24 | The Board of Trustees of the University of Illionis | Peptidhemmung von ccr3-vermittelten krankheiten oder zuständen |
AU2016281189B2 (en) | 2015-06-15 | 2019-03-07 | Hudson Institute of Medical Research | IL-37 variants |
US10703786B2 (en) | 2015-10-30 | 2020-07-07 | The University Of Melbourne | Methods and compositions for improving glucose metabolism |
CN108490177B (zh) * | 2018-02-08 | 2020-12-29 | 深圳市新产业生物医学工程股份有限公司 | 鼻咽癌抗体检测试剂、其制备方法及鼻咽癌检测试剂盒 |
JP2022543056A (ja) | 2019-07-29 | 2022-10-07 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイ | 創傷治癒を促進するための組成物および方法 |
WO2021123173A1 (en) | 2019-12-20 | 2021-06-24 | F. Hoffmann-La Roche Ag | Il-37 fusion proteins and uses thereof |
WO2022109053A1 (en) | 2020-11-18 | 2022-05-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Tyrosyl-lock peptides |
WO2023192802A1 (en) | 2022-04-01 | 2023-10-05 | The Board Of Trustees Of The University Of Illinois | Notch1 and notch4 decoys and methods of use |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE45285T1 (de) * | 1983-11-07 | 1989-08-15 | Wistar Inst | Durch antiidiotype antikoerper induzierte immune antwort zu tumoren und viren. |
US4699880A (en) * | 1984-09-25 | 1987-10-13 | Immunomedics, Inc. | Method of producing monoclonal anti-idiotype antibody |
IE873041L (en) * | 1987-11-11 | 1989-05-11 | Ailbe Brennan | Viral antigens, diagnostic assay therefor and vaccines¹containing them |
WO1991002091A1 (en) * | 1989-08-10 | 1991-02-21 | Northwestern University | Method of identifying herpesviruses and oligonucleotides for use therein |
WO1991008224A1 (en) * | 1989-11-24 | 1991-06-13 | The Council Of The Queensland Institute Of Medical Research | Im peptides |
ES2064082T3 (es) * | 1989-12-20 | 1995-01-16 | Schering Corp | Proteinas bcrf1 como inhibidores de interferon-gamma. |
JPH04310861A (ja) * | 1991-04-09 | 1992-11-02 | Kazuo Yanagi | 抗ebna抗体の測定方法および抗ebna抗体測定キット |
-
1993
- 1993-03-10 AT AT93200691T patent/ATE222291T1/de not_active IP Right Cessation
- 1993-03-10 ES ES93200691T patent/ES2184735T3/es not_active Expired - Lifetime
- 1993-03-10 EP EP02075193A patent/EP1225226B1/de not_active Expired - Lifetime
- 1993-03-10 EP EP93200691A patent/EP0574048B1/de not_active Expired - Lifetime
- 1993-03-10 DK DK93200691T patent/DK0574048T3/da active
- 1993-03-10 AT AT02075193T patent/ATE380243T1/de not_active IP Right Cessation
- 1993-03-10 ES ES02075193T patent/ES2298325T3/es not_active Expired - Lifetime
- 1993-03-10 PT PT93200691T patent/PT574048E/pt unknown
- 1993-03-10 DE DE69334191T patent/DE69334191T2/de not_active Expired - Lifetime
- 1993-03-10 DK DK02075193T patent/DK1225226T3/da active
- 1993-03-10 DE DE69332197T patent/DE69332197T2/de not_active Expired - Lifetime
- 1993-03-12 ZA ZA931797A patent/ZA931797B/xx unknown
- 1993-03-12 FI FI931109A patent/FI114802B/fi not_active IP Right Cessation
- 1993-03-12 AU AU35152/93A patent/AU666920B2/en not_active Expired
- 1993-03-12 US US08/031,148 patent/US5424398A/en not_active Expired - Lifetime
- 1993-03-12 CA CA002092680A patent/CA2092680C/en not_active Expired - Lifetime
- 1993-03-13 KR KR1019930003940A patent/KR100291247B1/ko not_active IP Right Cessation
- 1993-03-15 JP JP08009993A patent/JP4135996B2/ja not_active Expired - Lifetime
-
2004
- 2004-03-31 JP JP2004102197A patent/JP4106041B2/ja not_active Expired - Lifetime
-
2008
- 2008-03-31 JP JP2008089543A patent/JP4365440B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
PT574048E (pt) | 2002-12-31 |
DE69334191D1 (de) | 2008-01-17 |
JP4135996B2 (ja) | 2008-08-20 |
FI931109A (fi) | 1993-09-14 |
CA2092680C (en) | 2006-08-08 |
FI931109A0 (fi) | 1993-03-12 |
CA2092680A1 (en) | 1993-09-14 |
DK0574048T3 (da) | 2002-12-16 |
EP1225226A1 (de) | 2002-07-24 |
EP0574048B1 (de) | 2002-08-14 |
KR930019829A (ko) | 1993-10-19 |
DK1225226T3 (da) | 2008-04-14 |
DE69334191T2 (de) | 2008-11-27 |
EP0574048A2 (de) | 1993-12-15 |
ATE380243T1 (de) | 2007-12-15 |
JP4365440B2 (ja) | 2009-11-18 |
AU666920B2 (en) | 1996-02-29 |
EP0574048A3 (de) | 1994-03-02 |
JP2004261183A (ja) | 2004-09-24 |
KR100291247B1 (ko) | 2001-06-01 |
EP1225226B1 (de) | 2007-12-05 |
ES2184735T3 (es) | 2003-04-16 |
ATE222291T1 (de) | 2002-08-15 |
DE69332197D1 (de) | 2002-09-19 |
JP4106041B2 (ja) | 2008-06-25 |
ZA931797B (en) | 1993-09-30 |
JP2008261851A (ja) | 2008-10-30 |
ES2298325T3 (es) | 2008-05-16 |
US5424398A (en) | 1995-06-13 |
JPH0690787A (ja) | 1994-04-05 |
AU3515293A (en) | 1993-09-16 |
DE69332197T2 (de) | 2003-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI114802B (fi) | Epstein-Barr-virukseen liittyviä peptidejä ja nukleiinihapposekvenssejä | |
CA1335429C (en) | Processes for the production of hcmv glycoproteins, antibodies thereto and hcmv vaccines, and recombinant vectors therefor | |
JP4612071B2 (ja) | エプスタイン−バールウイルスペプチド及び該ペプチドに対する抗体 | |
Van Grunsven et al. | Gene mapping and expression of two immunodominant Epstein-Barr virus capsid proteins | |
US6337074B1 (en) | Anti-herpesviral agent | |
JP4957974B2 (ja) | エプスタイン・バールウイルスのペプチド及びこれらのペプチドに対する抗体 | |
US7507804B2 (en) | Peptides and nucleic acid sequences related to the Epstein Barr Virus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MA | Patent expired |